Vascular pathology in patients with idiopathic Parkinson's disease

Movement Disorders Centre and Stroke Centre, First Department of Neurology, Masaryk University, St. Anne's Teaching Hospital, Pekarska 53, 656 91 Brno, Czech Republic.
Parkinsonism & Related Disorders (Impact Factor: 3.97). 05/2008; 15(1):24-9. DOI: 10.1016/j.parkreldis.2008.02.007
Source: PubMed


To study the impact of brain vessel pathology on the clinical status of Parkinson's disease (PD), in 57 consecutive patients the clinical and neuropsychological data were compared with clinical MRI signs of vascular impairment and with the ultrasound brain vessel investigations. There was a significant correlation between clinical and cognitive status and intimomedial thickness, which is an indicator of large vessel impairment. Cognitive status was significantly related to the pulsatility index (an indicator of small vessel impairment). This study provides evidence that subclinical vascular pathology could influence the clinical status by contributing to motor and cognitive dysfunction in PD.

20 Reads
  • Source
    • "The patient cohort was defined by the investigation of the inflammatory biomarkers. This cohort is part of a larger welldescribed cohort that was studied with respect to vascular factors and published elsewhere [19] [20]. A baseline examination of the immunomarkers (IL-6, TNF-í µí»¼, C-reactive protein, serum amyloid A, alpha 1-anti- trypsin, orosomucoid, ceruloplasmin, alpha 2-macroglob- ulin, transferrin, prealbumin, MBL) and factors of the complement system (C1q, C1-INH, C3, and C4) in serum was performed on 53 patients in 2005. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives. The association between abnormal serum immunomarkers and mortality in 53 consecutive Parkinson's disease patients was studied. Materials and Methods. The plasma level of specific inflammatory cytokines was investigated: mannan-binding lectin (MBL), interleukin- (IL-) 6, and tumor necrosis factor-alpha (TNF-α). The baseline serum immunomarkers obtained from patients who died (n = 16) during a four-year follow-up period were compared with the data of patients who survived (n = 37). Results. The baseline level of IL-6 was significantly higher in the deceased patients than in the survivors. Elevated IL-6 levels and age were major independent contributors to disease mortality. Differences between other plasma cytokine level abnormalities were not significant. Conclusion. This study showed that IL-6 elevation may be a marker of increased mortality risk in Parkinson's disease patients. The inflammation may act in association with other factors and comorbidities in progressive neurodegenerative pathology.
    Parkinson's Disease 09/2015; 2015(1):898192. DOI:10.1155/2015/898192 · 2.01 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: It is our premise that the pathophysiology of small vessel disease in the brain is similar to small vessel disease in other heavily perfused tissues and that the presence of small vessel disease elsewhere in the body foretells its presence in the brain as well as its consequences on cognitive function. The hypothesis presented in this article is that small vessel disease is a systemic condition of aging that is exacerbated by vascular risk factors, which results from dysfunction of arteriolar perfusion. This condition, which we term systemic arteriolar dysfunction, affects the brain as well as a number of extracranial systems. Recent literature is synthesized to suggest a possible etiology of this condition, highlighting the multiple pathways that may conspire to produce the endothelial and other vascular changes seen in systemic arteriolar dysfunction. Regardless of the etiology, we emphasize that small vessel disease is a systemic condition with major healthcare consequences, requiring a new paradigm in the way we practice medicine. Because this condition can be decelerated by control of vascular risk factors, doing so may significantly reduce morbidity, mortality, and healthcare costs.
    Stroke 03/2009; 40(5):e322-30. DOI:10.1161/STROKEAHA.108.542266 · 5.72 Impact Factor
  • Parkinsonism & Related Disorders 08/2009; 16(1). DOI:10.1016/j.parkreldis.2009.07.004 · 3.97 Impact Factor
Show more